Verapamil attenuates the malignant treatment course in recurrent status epilepticus

Epilepsy and Behavior

Volumn 17, Issue 4, 2010, Pages 565-568

  Schmitt, Friedhelm C ^a,b   Dehnicke, Christoph ^b   Merschhemke, Martin ^b   Meencke, Heinz Joachim ^b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Malignant; Multidrug transporter; P glycoprotein; Pharmacoresistance; Recurrent; Refractory; Status epilepticus; Verapamil

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GLYCOPROTEIN P; LAMOTRIGINE; LORAZEPAM; MESUXIMIDE; METOCLOPRAMIDE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PROPOFOL; STEROID; THIOPENTAL; TOPIRAMATE; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

ADULT; ANOREXIA; ARTICLE; CASE REPORT; CONSCIOUSNESS DISORDER; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; EPILEPTIC STATE; FEMALE; FRONTAL LOBE EPILEPSY; HEART ARRHYTHMIA; HUMAN; HYPERTHERMIA; MACULOPAPULAR RASH; MALAISE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOOD DISORDER; MYOPATHY; NEUROPATHY; NYSTAGMUS; OROFACIAL DYSKINESIA; PARALYTIC ILEUS; PNEUMONIA; PSYCHOMOTOR DISORDER; QUADRIPLEGIA; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN MANIFESTATION; TACHYCARDIA; TONIC SEIZURE;

CALCIUM CHANNEL BLOCKERS; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; RECURRENCE; STATUS EPILEPTICUS; VERAPAMIL; YOUNG ADULT;

EID: 77952243806     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.01.166     Document Type: Article

References (25)

1. Holtkamp M. The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol 2007, 20:188-193.
2. Ropper AH, Gress DR, Diringer MN, Green DM, Mayer SA, Bleck TP. Status epilepticus. In: Ropper AH, Gress DR, Diringer MN, Green DM, Mayer SA, Bleck TP. Neurological and neurosurgical intensive care. Lippincott Williams & Wilkins; 2004. p. 314-21.
3. Rogawski M., Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004, 5:553-564.
4. Wasterlain C.G., Chen J.W.Y. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008, 49(Suppl. 9):63-73.
5. Holtkamp M., Othman J., Buchheim K., et al. A 'malignant' variant of status epilepticus. Arch Neurol 2005, 62:1428-1431.
6. Löscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia 2007, 48(Suppl. 8):74-77.
7. Kwan P., Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46:224-235.
8. Miller D.S., Bauer B., Hartz A.M. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 2008, 60:196-209.
9. Luna-Tortos C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
10. Rossetti A., Logroscino G., Bromfield E. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005, 62:1698-1702.
11. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
12. Cohen A.S., Matharu M.S., Goadsby P.J. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 2007, 69:668-675.
13. Hesdorffer D.C., Logroscino G., Cascino G., et al. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998, 44:908-912.
14. Chin R., Neville B., Scott R. A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004, 11:800-810.
15. Shinnar S., Maytal J., Krasnoff L., et al. Recurrent status epilepticus in children. Ann Neurol 1992, 31:598-604.
16. Summers M.A., Moore J.L., McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004, 38:1631-1634.
17. Majkowski J., Patsalos P. Pharmacokinetic interactions: interactions between antiepileptic and non-antiepileptic drugs. Antiepileptic drugs: combination therapy and interactions 2005, 139-178. Press Syndicate of the Univ. of Cambridge, Cambridge. J. Majkowski, B. Bourgeois, P. Patsalos, R. Mattson (Eds.).
18. Iannetti P., Spalice A., Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005, 46:967-969.
19. Iannetti P., Parisi P., Spalici A., Ruggieri M., Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 2009, 85:89-95.
20. Luszczki J.J., Trojnar M.K., Trojnar M.P., Kimber-Trojnar Z., Szostakiewicz B., Zadrozniak A., et al. Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 2007, 59:672-682.
21. Kułak W., Sobaniec W., Wojtal K., Czuczwar S.J. Calcium modulation in epilepsy. Pol J Pharmacol 2004, 56:29-41.
22. Wurpel J.N., Iyer S.N. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 1994, 35(2):443-449.
23. Schmidt D., Ried S. Clinical relevance of calcium antagonists in the treatment of epilepsy. Arzneimittelforschung 1989, 39:156-158.
24. De Sarro G.B., Meldrum B.S., Nisticó G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 1988, 93:247-256.
25. Besser R., Krämer G. No evidence for efficacy of intrathecal verapamil in the treatment of tonic-clonic status epilepticus. J of Epilepsy 1992, 5:61-63.